Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
Pharma industry veteran brings more than two decades of experience in sales, marketing, business development, and global market expansion to his new leadership role
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
